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Immunotherapy is revolutionizing approaches to cancer 
treatment. Monoclonal antibodies that inhibit specific im-
mune pathways, such as programmed cell death protein 
1 (PD-1) and PD-ligand 1 (PD-L1), are used to boost 
immune response against cancer cells (1). However, 
antibodies targeting PD-1/PD-L1 can provoke immune-
related adverse events (irAEs), which often manifest as 
skin changes. Among cutaneous irAEs, approximately 
8% are immunobullous in nature, commonly bullous 
pemphigoid (BP) (2). 
The pathogenesis of anti-PD-1/PD-L1-associated BP 
is not fully understood. BP180, a basement membrane 
protein, is expressed in some tumour cells, and persistent 
immune activation induces antibody production against 
both tumour and normal skin (3). In this context, more 
serious cutaneous irAEs can be expected in novel cancer 
immunotherapies boosting anti-PD-1/PD-L1-induced 
immune responses.We report here a case series of BP 
associated with combined treatment using anti-PD-1/
PD-L1 antibodies and novel agents targeting transforming 
growth factor (TGF)-β, an immunosuppressive cytokine 
upregulated in the cancer microenvironment (4, 5). 
MATERIALS, METHODS AND RESULTS
This study retrospectively reviewed the medical records of 46 BP 
patients selected based on the following criteria: BP diagnosis 
based on clinical and histological findings including direct and/or 
indirect immunofluorescence at Severance Hospital, Seoul, Korea, 
between 2017 and 2021. Among the 46 cases, 10 were identified 
as anti-PD-1/PD-L1-induced BP (Table SI1). Four of them were 
treated the combined regimen of anti-PD-1/PD-L1 and TGF-β 
inhibitor (TGFβi) (combination group); 6 patients were treated 
with anti-PD-1/PD-L1 only (monotherapy group). The culprit 
anti-PD-1/PD-L1 drugs included pembrolizumab, nivolumab, and 
durvalumab. TGFβi agents included vactosertib (TEW-7197), a 
selective small molecule inhibitor of TGF-β receptor type 1  and 
bintrafusp alfa (M7824), a bifunctional fusion protein composed 
of an antibody directed to PD-L1 fused to the extracellular domain 
of human TGF-β receptor type 2 (4, 5). There were 36 patients 
diagnosed with BP that was not associated with any cancer im-
munotherapy (idiopathic group, Table SII1).
Using clinical images, patients’ Autoimmune Bullous Skin 
Disorder Intensity Scores (ABSIS) and Bullous Pemphigoid 
Disease Area Index (BPDAI) scores were assessed (6). To assess 
regional severity on acral areas; both hands and both feet were 
ascribed separate severity scores of 0–4 (0: none; 1: < 25%; 2: 
25–50%; 3: 50–75%; 4: > 75% involvement). Statistical analysis 
was performed using Kruskal-Wallis H tests and Dunn’s multiple 
comparison tests. 
There was no statistical difference in age between the idiopathic, 
monotherapy, and combination groups (p = 0.32; Tables SI and 
SII1). The incubation time from the start of immunotherapy to BP 
onset was not different between the monotherapy vs combination 
groups (313.8 vs 241.0 days, p = 0.10).
Severity evaluation using ABSIS found a higher mean score in 
the combination group (43.6 points) compared to the idiopathic 
group (5.08 points, p = 0.007, Fig. S1A1). The mean BPDAI was 
higher in the combination group (116.5 points) than the monoth-
erapy group (22.7 points, p = 0.040) and the idiopathic group (18.6 
points, p = 0.003, Fig. S1B1).  
Mucosal involvement was reported in 2 patients in the mon-
otherapy group (33%) and 2 patients in the combination group 
(50%), which was significantly higher (p = 0.018, Fisher’s exact 
test) than the idiopathic group (n = 2, 5.5%). However, mucosal 
involvement was limited to oral mucosa, and the overall severity 
was mild in all reported cases.
Systemic glucocorticoid treatment dosage, which can indirectly 
reflect severity of BP, was evaluated as prednisolone-equivalent 
dose (mg/kg). A peak steroid dose of 1.22 mg/kg was necessary 
for control of acute flare in the combination group, which was a 
higher dose than either the monotherapy (0.54 mg/kg, p = 0.09) or 
idiopathic group (0.35 mg/kg, p = 0.005) (Fig. S1C1). Correspon-
dingly, the mean lowest steroid dose sufficient for maintenance in 
the combination group required a higher dose (0.30 mg/kg) than 
the monotherapy (0.10 mg/kg, p = 0.25) or idiopathic group (0.06 
mg/kg, p = 0.003) (Fig. S1D1). 
Patients in the combination group presented a patterned distribu-
tion with an acral predilection for hands and feet (Fig. 1). With a 
maximum possible score of 8 (0–4 scoring for hands, 0–4 scoring for 
feet), the combination group had a mean value of 6.50 points, which 
was significantly higher than monotherapy (0.67 points, p = 0.006) 
or idiopathic BP (1.19 points, p = 0.003) groups (Fig. S1E1).
DISCUSSION
This case series documented severe, distinctively-patter-
ned anti-PD-1/PD-L1-associated BP in patients treated 
with a TGFβi combination regimen. Moreover, a greater 
requirement on steroid dosage to control disease activity 
suggests that BP symptoms induced by this novel combi-
nation regimen are more difficult to manage. 
Most patients in the monotherapy group reached the 
minimal dose or discontinuation of systemic steroids after 
discontinuation of the immunotherapy regimen. However, 
the combination group had a significantly more severe 
and protracted disease course. For instance, exceptio-
nally high dosages (>1.3 mg/kg/day) of systemic steroids 
(e.g. case 1, 2) or additional immunosuppressants (e.g. 
case 3, 4) were required to prevent development of new 
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blisters until withdrawal of the culprit drug (Table SI1). 
Notably, the culprit drug was discontinued more rapidly 
in the combination group (mean, 4.5 days) than in the 
monotherapy group (37.7 days), suggesting that delayed 
drug discontinuation was not the cause of a more severe 
phenotype. In addition, patients in the combination group 
experienced frequent (50%) mucosal involvement of BP, 
further indicating a more severe disease presentation.
These findings indicate the importance of TGF-β 
signalling in restricting autoimmune bullous disease, 
particularly in cutaneous irAEs. This may be due to the 
role of the TGF-β signalling pathway for prevention of 
self-reactive B-cell activation and autoantibody produc-
tion (7). TGF-β signalling also plays a key role in the 
proliferation of regulatory T cells, which produce IL-10 
and TGF-β to promote immune regulation (8). Thus, dis-
ruption of this complex regulatory interaction may further 
reinforce ongoing inflammatory processes and result in a 
more severe BP presentation.
TGFβi combination regimen-induced BP had a greater 
predilection for acral areas. Considering the essential 
role of the TGF-β/Smad signalling pathway during limb 
regeneration or the preferential expression of TGF-β in 
the limbs vs the trunk during wound healing in animal 
models (9), imbalance of TGF-β, a pleiotropic signal, may 
be related to vulnerability of inflammatory processes in 
specific anatomical locations.
Since this study was a retrospective case series was 
performed at a single institution with a small group, future 
studies that include larger subject populations are required. 
Due to medical insurance guidelines in Korea, we were 
unable to measure serum levels of anti-BP180 autoantibody, 
which may be insightful in explaining the development of 
this distinctively-patterned and severe BP. Nonetheless, this 
study displays a relationship between the use of the TGFβi 
combination regimen and anti-PD-1/PD-L1-associated BP 
which implies the important role of TGF-β signalling for 
restricting development of autoimmune skin toxicity.
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Fig. 1. Clinical presentations of anti-programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1)-associated bullous pemphigoid induced 
by a combination regimen including transforming growth factor-β inhibitors. (a) Case 1: extensive erosions induced by (b, c) bullae and severe 
involvement of acral areas. (d) Case 3: widespread erosions that originated from (e) typical tense bullae and (f) severe palmar involvement.
